- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04191668
A Validation Study of the NightOwl PAT-based Home Sleep Apnea Test
Study Overview
Detailed Description
The objective of this study is to evaluate the performance of a miniaturized sleep apnea test, called NightOwl. The system consists of a sensor placed on the fingertip and a cloud-based analytics software. The sensor acquires accelerometer and photoplethysmographic data. The software derives actigraphy from the former, and blood oxygen saturation and peripheral arterial tone (PAT), among other features, from the latter. In order to assess NightOwl's performance, The investigators will compare the respiratory event index (REI), defined as the number of respiratory events per hour of sleep, derived by the NightOwl system, to the AHI obtained from manual analysis of the polysomnography (PSG), which is the gold standard for sleep apnea diagnosis. The investigators will also compare the total sleep time (TST) derived by both systems. This study will be performed in a sleep lab environment.
As of March 2017, the new clinical practice guideline for diagnostic testing for adult sleep apnea of the American Academy of Sleep Medicine (AASM) for the first time formulates a strong recommendation that both polysomnography (PSG) and home sleep apnea testing (HSAT) are appropriate diagnostic testing options for uncomplicated adult patients who are at increased risk of moderate to severe sleep apnea.
Collop et al. performed a comprehensive analysis of the evidence for HSAT devices to diagnose obstructive sleep apnea (OSA) in out-of-center settings. The authors concluded that testing devices that analyze changes in peripheral arterial tone (PAT) in combination with actigraphy and blood oxygen saturation (SpO2) are adequate to diagnose OSA in patient populations with a high pre-test probability.
In this study, the investigators wish to assess the performance of a system for the diagnosis of OSA that measures and analyzes the abovementioned parameters, called NightOwl. The system consists of a small sensor device which is placed on the fingertip and a cloud-based analytics platform.
It is designed to be self-applied and initiated by the patient by attaching the sensor to the fingertip by means of an adhesive patch.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Miami Lakes, Florida, United States, 33016
- Miami Lakes Laboratory
-
Plantation, Florida, United States, 33324
- Plantation Laboratory East
-
Plantation, Florida, United States, 33324
- Plantation Laboratory West
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with an indication for an in-lab polysomnography
Exclusion Criteria:
- Intellectually disabled people
- People younger than 13 years of age.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: PSG and NightOwl
Default patient recruitment During the study, for each execution day, all patients that have been scheduled for a PSG will be presented with an informed consent.
All recruited patients shall be a part of the study during which they wear the NightOwl Sensor while undergoing the PSG exam.
|
The NightOwl is a finger-mounted home sleep apnea testing device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pearson Correlation Between the AHI
Time Frame: Through study completion, an average of 1 month.
|
The evaluation of the Pearson correlation between the apnea-hypopnea index (AHI) estimate obtained from the NightOwl and the AHI determined from the polysomnography (PSG); The AHI is defined as the number of apnea or hypopnea divided by the (estimated) total sleep time expressed in hours.
|
Through study completion, an average of 1 month.
|
Pearson Correlation Between the TST
Time Frame: Through study completion, an average of 1 month.
|
The evaluation of the Pearson correlation between the total sleep time (TST) estimate obtained from the NightOwl and the TST determined from the PSG;
|
Through study completion, an average of 1 month.
|
The Evaluation of the Level of Agreement (Classification Accuracy) Between Patient Categorization
Time Frame: Through study completion, an average of 1 month.
|
The evaluation of the level agreement (classification accuracy) between patient categorization (into sleep apnea severity categories) obtained by the NightOwl and those obtained by the PSG.
This measure is calculated by dividing the number of participants on which both NightOwl and the PSG agree on the sleep apnea severity category by the total number of participants.
|
Through study completion, an average of 1 month.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Frederik Massie, MSc, Ectosense NV
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NightOwl-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Apnea
-
ResMedCRI-The Clinical Research Institute GmbH; University Hospital RegensburgCompletedObstructive Sleep Apnea | Central Sleep Apnea | Mixed Sleep Apnea | Complex Sleep ApneaSwitzerland, Spain, Denmark, Portugal, France, Germany
-
ResMedCompletedObstructive Sleep Apnea | Central Sleep Apnea (Diagnosis) | Chronic Opioid UseUnited States
-
Medtronic - MITGCompletedObstructive Sleep Apnea | Sleep Apnea | Sleep-Disordered Breathing | Central Sleep ApneaUnited States
-
ResMedRWTH Aachen UniversityRecruitingObstructive Sleep Apnea | Central Sleep Apnea | Mixed Sleep ApneaGermany
-
Somnarus IncCompletedObstructive Sleep Apnea | Cheyne-Stokes Respiration | Central Sleep Apnea | Mixed Sleep ApneaUnited States
-
University of California, Los AngelesRecruiting
-
Brigham and Women's HospitalCompletedObstructive Sleep Apnea (OSA)United States
-
LivaNovaRecruitingApnea | Obstructive Sleep Apnea | OSA | Apnea, Obstructive | Apnea+Hypopnea | Apnea, Obstructive Sleep | Hypopnea, SleepUnited States
-
The Hospital for Sick ChildrenRecruitingObstructive Sleep Apnea | Hypoventilation | Central Sleep ApneaCanada
-
The Hospital for Sick ChildrenCompleted
Clinical Trials on NightOwl
-
Herlev and Gentofte HospitalSygekassernes HelsefondCompletedObstructive Sleep ApneaDenmark
-
Ectosense NVActive, not recruiting
-
Ectosense NVUnknown
-
Ectosense NVZiekenhuis Oost-LimburgUnknown
-
Ectosense NVZiekenhuis Oost-LimburgUnknown
-
Herlev and Gentofte HospitalRecruitingAtrial Fibrillation | Sleep ApneaDenmark
-
Steno Diabetes Center GreenlandZealand University Hospital; University of CopenhagenRecruitingDiabetes Mellitus, Type 2 | Diabetic Neuropathies | Diabetic Retinopathy | Obstructive Sleep Apnea | Obesity, Morbid | MODYGreenland